Rexam Healthcare expands its manufacturing capabilities in Normandy, France
5 June, 2013
Rexam Healthcare, a subsidiary of the UK group Rexam, has announced the expansion of manufacturing capabilities at its French site in Le Tréport, Seine Maritime.
This site specialises in drug delivery systems and recently introduced the acclaimed Advancia® pump, the design and development of which was co-financed by the European Regional Development Fund in Normandy.
With over 50 years' expertise in assembly and injection moulding, the Rexam plant at Le Tréport not only provides "standard" devices but prides itself on anticipating the market's growing regulatory requirements, using its capacity for innovation to the benefit of patients. It works in close collaboration with the La Verpillière Innovation Design Centre, near Lyon.
Along with other site improvements, Rexam Healthcare is investing in the expansion of its manufacturing unit: a total workspace of 5200 m2; a production building boasting 3750 m2 including a clean room of 2900 m2; and 1500 m2 housing the machine and mould maintenance workshops, metrology unit, laboratory and administrative premises.
In total, this extensive project is costing over 20 million € included within overall group guidance for capital expenditure.
The construction work is only possible thanks to the environmental protection measures implemented as part of the project, along with the valued support of the Sub-Prefect of Dieppe, Ms Laquieze, the Mayor of Le Tréport, Alain Longuent, and Ms Brière from the Planning Department.
In fact, work on the extension is not simply about "manufacturing capacity" for Rexam. It has also conducted an in-depth study on the environment and compensatory measures at an equivalent plot of land in the La Bresle valley, resulting in an environmental management plan and measures to restore wetland areas.
Nearly 200 employees currently work at the site. The extension, coupled with the Advancia® project supported by the ERDF, will create approximately fifty new jobs for the region.
With the cleanroom due to open in November 2013 and full inauguration of the site scheduled for early 2014, Rexam Healthcare is ensuring it has the resources to meet the needs of even its largest customers, as well as to welcome new projects.
Rexam's vision is to be the best global consumer packaging company. We are also one of the world's leading beverage can manufacturers and a major global player in the rigid plastic packaging market.
We work in partnership with major consumer brands as well as with up-and-coming enterprises. Rexam's turnover for 2012 was around 4.3 billion pounds. We have more than 69 factories and employee 11,000 people. Rexam is listed on the FTSE 100 and ordinary shares are registered with the UK Listing Authority and traded on the London stock exchange under the code REX.
Rexam Healthcare is a leading provider of drug delivery systems and medical devices for the pharmaceutical, medical and biotechnology industries. Building on our core expertise in plastic injection, injection blow moulding and high speed automated assembly, we design, develop and manufacture innovative packaging, including containers and closures, drug delivery systems, pumps and valves and medical components designed to improve patients' health.
We have designed our four business units: Devices, Containers & Closures, Prescription Retail and International & Emerging Markets to meet the unique needs of each of our customers.
Focussing entirely on the healthcare sector, we also offer our customers in-depth regulatory knowledge and the reassurance of best manufacturing practices. With over 3000 employees and 14 sites across 3 continents, Rexam Healthcare is the world's leading rigid plastic packaging and medical devices provider.